Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
109 Leser
Artikel bewerten:
(0)

Sysmex America Signs Distribution Agreement with Henry Schein

LINCOLNSHIRE, Ill., March 11, 2014 /PRNewswire/ --Sysmex America, Inc., a global leader in medical diagnostic testing equipment and information systems technology, and Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, today announced the signing of a three-year distribution agreement between the companies effective immediately. Under the agreement, Henry Schein will represent Sysmex's pocH-100i', XP-300', XN-1000', XN-2000', XS-1000i' and the XT-4000i' automated hematology analyzers in the alternate care setting,

Sysmex America, Inc. Logo

"Like Sysmex America, Henry Schein is fully committed to serving customers with the highest level of service and support," said Andy Hay, Vice President of Sales, Sysmex America. "This commitment, coupled with Henry Schein's excellent local coverage across the U.S., enables our customers with quick access to high-quality hematology analyzers that are supported by high-quality service, support and training. We look forward to a long-term working relationship with Henry Schein."

"As a market leader in clinical laboratory diagnostics and services, we know that Sysmex America manufactures reliable and easy-to-use hematology analyzers. This combination is the right fit for our non-acute care customer base," said Dominick Gallo, VP, Product Management, Henry Schein. "The agreement gives us an opportunity to offer an even broader portfolio of onsite lab testing, enabling customers to diagnose and treat patients in the office, greatly improving the patient experience and expediting care."

All of Sysmex's hematology product offerings covered under the Henry Schein distribution agreement include standard support service, on-site installation and training. For more information about Sysmex automated hematology analyzers for the non-acute care setting, health care professionals can visit the company's website at www.sysmex.com/us.

About Henry Schein, Inc.

Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein employs more than 16,000 Team Schein Members and serves more than 800,000 customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 96,000 branded products and Henry Schein private-brand products in stock, as well as more than 110,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services. Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries. The Company's sales reached a record $9.6 billion in 2013, and have grown at a compound annual rate of nearly 17% since Henry Schein became a public company in 1995. For more information, visit the Henry Schein website at www.henryschein.com.

About Sysmex America, Inc.

Sysmex America, Inc., in Lincolnshire, Illinois, the U.S. headquarters of Sysmex Corporation (Kobe, Japan), is a trusted world leader in clinical laboratory systemization and solutions that optimize the clinical utility, operational efficiency and financial performance of the lab. Sysmex America distributes and supports a diversified portfolio of best-in-class automated in vitro diagnostic hematology, coagulation and urinalysis analyzers, reagents and information systems for laboratories and healthcare facilities throughout the Western Hemisphere. The Company's unwavering commitment to clinical excellence and technological innovation is reflected in the Sysmex brand and its distinguished heritage of unsurpassed reliability. Sysmex is reshaping the healthcare of tomorrow at the clinical laboratory level by transcending the boundaries of diagnostic science and serving as the pulse of reliable, accountable care. For more information about Sysmex, please visit www.sysmex.com/us

Logo- http://photos.prnewswire.com/prnh/20130612/CG30721LOGO-b

SOURCE Sysmex America, Inc.

© 2014 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.